XBiotech (NASDAQ:XBIT) Releases Quarterly Earnings Results

XBiotech (NASDAQ:XBIT) announced its earnings results on Friday. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, FiscalAI reports.

XBiotech Price Performance

Shares of NASDAQ:XBIT traded up $0.00 on Friday, reaching $2.34. 1,357 shares of the company traded hands, compared to its average volume of 38,454. The stock has a market capitalization of $71.47 million, a PE ratio of -2.43 and a beta of 0.87. The company’s 50 day moving average is $2.45 and its 200-day moving average is $2.54. XBiotech has a fifty-two week low of $2.09 and a fifty-two week high of $3.62.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of XBiotech in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On XBiotech

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd raised its holdings in XBiotech by 44.1% during the 4th quarter. XTX Topco Ltd now owns 21,703 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 6,647 shares during the period. Bridgeway Capital Management LLC increased its position in shares of XBiotech by 50.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 89,547 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 30,000 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of XBiotech during the fourth quarter valued at approximately $32,000. State Street Corp raised its holdings in shares of XBiotech by 8.5% during the fourth quarter. State Street Corp now owns 73,006 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 5,700 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of XBiotech by 25.1% in the 4th quarter. Jane Street Group LLC now owns 69,738 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 13,971 shares in the last quarter. 55.70% of the stock is owned by hedge funds and other institutional investors.

XBiotech Company Profile

XBiotech Inc is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company’s core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech’s lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.

The company’s most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients.